# Bio/Healthcare Investment - Accent Therapeutics ('24.01, Series C)

# Bio/Healthcare Investment - Strategic investment for Samsung's Bio business affiliates - Financial investment - Market Intelligence for focused investment area - Achievement: Senda Biosciences (Series C, $15M), Araris Biotech AG (Pre-A, undisclosed)# New Fund raised - New CVC fund raised (\20B Korean Won)

# Open Innovation (R&D pipeline Licensing and strategic partnership) - NASH and Metabolic pipeline sourcing, review, business development - Oncology and Cell & Gene Therapy, Business development - Research market intelligence and internal reports - Leading due diligence and contract negotiation - Achievements: NASH asset licensing ('20.08)# Licensing Out - Commercial/Research stage pipeline out-licensing - Make long/short list of specific research area/territory and contact - Contract negotiation and execution - Achievement: Clinical asset L/O to Korean biotech ('19.02), Commercial asset L/O to Brazilian company ('20.09)# Managing internal/external Funds - Cooperate with internal financing and relevant team to report Management Team - Close communication with external/internal open innovation channel including PEF GP - Interact with Global Venture Capitals

# Portfolio Management & Developing New product pipeline - New product market research (Global including KR, CN, TH, VN, IN) - Sales forecasting and evaluation of profitability using DCF - Managing the product portfolio and New pipeline suggestion/planning/development - Managing internal development pert # New Business strategy Planning (Corporate global Business) - Product portfolio development of overseas affiliates - Analysis of China insurance/tender system and planning/development of new products - Collaboration with Local (China) Pharmaceutical university & research center - KOL/CFDA/CRO meeting for market/regulatory feasibility analysis - Investment feasibility analysis for new product, comparison with Korean manufacturer # New Business strategy Planning (CDMO, M&A, JV) - CDMO business planning : Analysis of local pharmaceutical companies and FDI environment : Review and analysis of current business portfolio and partner pool, business structure : Business development (Pool-up, Contact, Nego), Target product portfolio development - Merge and Acquisition (M&A), Strategic Investments : Company profile review, Advisor contracts, FDI (foreign direct investment) regulation and industrial environment analysis, Due diligence coordination, Synergy plan development, PMI (Post merge integration) strategy planning, Negotiation with target company with partners, Valuation : Collaboration with VC, IB, Financial advisors, Legal advisors